OxStem Limited has today announced the appointment of Dr. Georg C. Terstappen to the role of Chief Scientific Officer (CSO), following a successful executive search by The RSA Group.
Dr. Terstappen brings to OxStem over 25 years of leading roles in pharmaceutical R&D at international companies including Bayer, GlaxoWellcome, GSK, and Abbot/AbbVie. In addition, to these roles, he also co-founded and served as CSO of a start-up drug discovery company, Siena Biotech S.p.A. His major accomplishments in terms of innovative research and its practical application are demonstrated by 80 scientific publications, 15 patents and identification/development of many new drug targets, bioassay systems, biomarkers, drug delivery technologies and preclinical/clinical drug candidates.
Dr. Andy Theodorou, Senior Consultant, and Thomas Schleimer, Partner, at The RSA Group commented: “It was a pleasure and a privilege to work with Oxstem’s scientific founders and leadership team on this fascinating project. Dr. Terstappen will bring a wealth of drug discovery and development expertise to this highly innovative and entrepreneurial young company recognised for its scientific excellence in medicinal chemistry and depth of disease knowledge. This complimentary expertise will ensure delivery of innovative medicines to patients which is central to Oxstem’s vision.”
To read the full release here: Oxstem Appoints Chief Scientific Office